Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a BTLA Agonist Antibody (Venanprubart) in Healthy Participants, Patients with Systemic Lupus Erythematosus, and Patients with Psoriasis: Results From Three Phase 1 Studies

Ähnliche Einträge

• Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, in Healthy Chinese Participants
  von: Jingjing Wang, et al.
  Veröffentlicht: (2025)
• Comparability of Elezanumab Safety, Tolerability, and Pharmacokinetics in Healthy Japanese, Chinese, and White Participants
  von: Hari V. Kalluri, et al.
  Veröffentlicht: (2024)
• Safety, Tolerability, and Pharmacokinetics of Single‐ and Multiple‐Ascending Doses of Sunobinop in Healthy Participants
  von: Alessandra Cipriano, et al.
  Veröffentlicht: (2024)
• Effect of Carbamazepine on the Pharmacokinetics of Erdafitinib in Healthy Participants
  von: Pharavee Jaiprasart, et al.
  Veröffentlicht: (2024)
• Randomized Phase 1 Studies Evaluating the Safety, Tolerability, Pharmacokinetics, and Target Occupancy of Zampilimab in Healthy Participants
  von: Jo Collier, et al.
  Veröffentlicht: (2026)